1-Methyl-pyrrolidin-2-carbonsaeure-ethylester | 30727-23-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Methyl-pyrrolidin-2-carbonsaeure-ethylester
• 英文别名: Hygrinsaeure-ethylester；Ethyl 1-methylpyrrolidine-2-carboxylate
• CAS: 30727-23-2
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: FBTUOHOLPTXSPX-UHFFFAOYSA-N

物化性质

• 沸点：
  83-84 °C(Press: 17 Torr)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Methyl-pyrrolidin-2-carbonsaeure-ethylester 在 乙醚 、 乙醇 、 sodium 作用下， 生成 1-Methyl-2-benzoyloxymethyl-pyrrolidin
  参考文献：
  名称：

  Pyrrolidinium Analogs of Choline and Betaine. Onium Compounds. XXI

  摘要：

  DOI：

  10.1021/ja01874a052
• 作为产物：
  描述：

  5-(Hydroxy-methyl-amino)-pentanoic acid ethyl ester 在 三乙胺 、 lithium diisopropyl amide 作用下， 生成 1-Methyl-pyrrolidin-2-carbonsaeure-ethylester
  参考文献：
  名称：

  氮上的分子内亲核取代。新的杂环合成

  摘要：

  已经制备了一系列的5-（二苯基膦基氧基氨基）戊酸酯。用适当的碱处理它们导致环化为脯氨酸衍生物。该反应是第一个报道的分子内氮亲核取代的情况。

  DOI：

  10.1016/0040-4039(95)01567-2

文献信息

• [EN] PRODRUGS OF MYELOPEROXIDASE INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE LA MYÉLOPEROXYDASE
  申请人：BIOHAVEN THERAPEUTICS LTD

  公开号：WO2021072140A1

  公开（公告）日：2021-04-15

  Disclosed are prodrugs of myeloperoxidase (MPO) inhibitors, methods of treating MPO related disorders, e.g., multiple system atrophy, amyotrophic lateral sclerosis, and Huntingtons disease, and methods of neuroprotection, which include administering to a patient in need thereof the prodrugs, pharmaceutical compositions including the prodrugs, and kits including the pharmaceutical compositions and instructions for use.

  揭示了髓过氧化物酶（MPO）抑制剂的前药，治疗MPO相关疾病的方法，例如多系统萎缩症、肌萎缩侧索硬化和亨廷顿病，以及神经保护方法，包括向需要的患者施用前药，包括前药的药物组合物，以及包括药物组合物和使用说明的工具包。
• [EN] ANTIBIOTIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIBIOTIQUES
  申请人：DISCUVA LTD

  公开号：WO2018037223A1

  公开（公告）日：2018-03-01

  The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

  本发明涉及公式（I）的抗生素化合物，含有这些化合物的组合物，以及使用这些化合物治疗细菌性疾病和感染的方法。这些化合物在治疗革兰氏阳性和/或革兰氏阴性细菌引起的感染和疾病方面具有应用，特别是在治疗由淋病奈瑟菌引起的感染和疾病方面。
• N-Aryl Diazaspirocyclic Compounds and Methods of Preparation and Use Thereof
  申请人：Bhatti Balwinder S.

  公开号：US20080214591A1

  公开（公告）日：2008-09-04

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文揭示了化合物、包含这些化合物的药物组合物以及其制备和使用方法。这些化合物是N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物，或这些化合物的前药或代谢物。芳基基团可以是五元或六元杂环环（杂芳基）。这些化合物和组合物可用于治疗和/或预防各种疾病或障碍，特别是那些以尼古丁胆碱能神经递质功能障碍为特征的障碍，包括涉及神经递质释放的神经调节障碍，如多巴胺释放。中枢神经系统障碍是另一个可以治疗和/或预防的障碍的例子，其特征是正常神经递质释放的改变。这些化合物和组合物还可用于缓解疼痛。这些化合物可以：（i）改变患者大脑中尼古丁胆碱能受体的数量，（ii）表现出神经保护作用，（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显的负面影响以及对骨骼肌产生明显的影响）。
• N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
  申请人：Bhatti Balwinder S.

  公开号：US20110105548A1

  公开（公告）日：2011-05-05

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文介绍了N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物以及这些化合物的前药或代谢物。芳基可以是五元或六元杂环环（杂芳基）。这些化合物和组合物可以用于治疗和/或预防各种条件或疾病，特别是那些以尼古丁乙酰胆碱神经递质功能障碍为特征的疾病，包括涉及神经递质释放的神经调节疾病，如多巴胺释放。中枢神经系统疾病是另一种可以治疗和/或预防的疾病，其特征是正常神经递质释放的改变。这些化合物和组合物也可以用于缓解疼痛。这些化合物可以：（i）改变患者大脑中尼古丁乙酰胆碱受体的数量，（ii）表现出神经保护效果，以及（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显负面影响和对骨骼肌产生明显影响等副作用）。
• N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20150322002A1

  公开（公告）日：2015-11-12

  The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X 2 , L, subscript m, X 1 , ring D, R 1 , and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  本发明提供了具有一般式(I)及其药学上可接受的盐的新化合物，其中变量RA、下标n、环A、X2、L、下标m、X1、环D、R1和RN的含义如本文所述，并且包含这种化合物的组合物以及使用这种化合物和组合物的方法。